CRL — CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
—
NYSE ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1100682 ·
Last close
$332.16
Market Cap
$15.92B
52W High
$379.63
52W Low
$146.20
ADV30
1,145,921
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 982,732,000 | 357,870,000 | 202,638,000 | 333,067,000 | 7,451,507,000 | 200,381,000 | 4,176,241,000 |
| Jun 2026 | 1,004,078,000 | 363,374,000 | 119,888,000 | -1,482,000 | 7,532,145,000 | 192,025,000 | 4,643,618,000 |
| Mar 2026 | 995,830,000 | 294,664,000 | 119,897,000 | -14,843,000 | 7,730,308,000 | 191,830,000 | 4,741,995,000 |
| Dec 2025 | 994,227,000 | 309,684,000 | 92,534,000 | -276,555,000 | 7,135,422,000 | 213,770,000 | 3,924,228,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$622,407,000
Investing CF
$-462,328,000
Financing CF
$-122,947,000
CapEx
$-222,773,000
Dividends Paid
—
Buybacks
$-324,201,000
EPS Diluted TTM
$0.91
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$1,705,362,000
Inventory
$319,638,000
Receivables
$735,305,000
ST Investments
—
EBIT TTM
$9,168,000
Pretax Income TTM
$-100,214,000
Interest Exp TTM
$109,382,000
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,976,867,072
EBITDA
$909,380,992
Free Cash Flow
$443,239,616
Enterprise Value
$18,872,907,776
Total Cash
$200,380,992
Total Debt
$2,851,930,112
Shares Out
47,917,467
Trailing EPS
$0.92
Book Value
$67.40
ROE
1.3%
ROA
4.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,015,382,000 | 401,136,000 | -144,338,000 | 7,135,422,000 | 3,924,228,000 | 3,164,630,000 | 737,646,000 |
| Dec 2024 | 4,049,989,000 | 442,347,000 | 10,297,000 | 7,528,345,000 | 4,020,267,000 | 3,461,503,000 | 734,577,000 |
| Dec 2023 | 4,129,409,000 | 617,261,000 | 474,624,000 | 8,195,001,000 | 4,536,003,000 | 3,596,882,000 | 683,898,000 |
| Dec 2022 | 3,976,060,000 | 650,975,000 | 486,226,000 | 7,602,770,000 | 4,579,265,000 | 2,976,293,000 | 619,640,000 |
TTM Snapshot
Revenues TTM
$3,998,987,000
NetIncome TTM
$-238,458,000
OpCashFlow TTM
—
Assets (Latest)
$7,532,145,000
Forward EPS
$12.84
Max Pain — expiry 2026-12-18
max pain strike: $230.00 · spot: $333.25 · call oi: 2,335 · put oi: 627
Expected Move to 2026-12-18:
±$38.25
(11.48%) —
implied range
$295.00 –
$371.50
· ATM straddle on $330.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ICLR | ICON PLC | $15.05B | $195.02 | — |
| MEDP | Medpace Holdings, Inc. | $18.27B | $653.09 | — |
| INCY | INCYTE CORP | $24.27B | $119.09 | — |
| LNTH | Lantheus Holdings, Inc. | $6.66B | $101.80 | — |
| IQV | IQVIA HOLDINGS INC. | $42.45B | $257.60 | — |
News headlines (Yahoo Finance, 1h cache)
Global Preclinical CRO Services Market Opportunities and Strategies to 2035 | Capitalize on AI, Oncology and Biomarkers with Charles River, WuXi AppTec, Eurofins and Pharmaron
2026-11-18 14:37 · Yahoo
Charles River Laboratories International (CRL) Recovers Following Cyclical Contraction
2026-11-18 14:01 · Yahoo
Should You Continue to Hold Charles River Stock in Your Portfolio?
2026-11-18 13:47 · Yahoo
Charles River Laboratories International (CRL) Opens Dublin Site and South Korea Depot
2026-11-17 17:16 · Yahoo
Charles River Laboratories (CRL) Stock Looks Fairly Valued Despite Its 106% Run
2026-11-17 16:11 · Yahoo
Trumid and Charles River Expand Fixed Income Integration with FVMP™ Predictive Bond Pricing
2026-11-17 13:00 · Yahoo
Charles River Laboratories to Present at Jefferies Global Healthcare Conference
2026-11-16 21:30 · Yahoo
Non-Animal Alternative Testing - Global Strategic Business Report 2026: Capitalize on 13.3% CAGR and $4.7B by 2032 as Abbott, Charles River, Emulate, Evotec, and Bio-Rad Reshape Testing
2026-11-16 15:45 · Yahoo
Humanized Mouse and Rat Model - Global Strategic Business Report 2026: Capitalize on 9.7% CAGR to $231.6M by 2032 as Charles River, Biocytogen, Taconic and The Jackson Laboratory reshape drug R&D
2026-11-16 15:41 · Yahoo
Mice Model - Global Strategic Business Report 2026: Capitalize on a $3.4 Billion Market by 2032 as Charles River, LabCorp, Taconic Biosciences and The Jackson Laboratory Accelerate CRISPR
2026-11-16 15:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.